Logo image of KZR

KEZAR LIFE SCIENCES INC (KZR) Stock Fundamental Analysis

NASDAQ:KZR - Nasdaq - US49372L2097 - Common Stock - Currency: USD

4.26  -0.26 (-5.75%)

After market: 4.21 -0.05 (-1.17%)

Fundamental Rating

2

Taking everything into account, KZR scores 2 out of 10 in our fundamental rating. KZR was compared to 558 industry peers in the Biotechnology industry. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability. KZR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KZR has reported negative net income.
KZR had a negative operating cash flow in the past year.
In the past 5 years KZR always reported negative net income.
KZR had a negative operating cash flow in each of the past 5 years.
KZR Yearly Net Income VS EBIT VS OCF VS FCFKZR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

KZR's Return On Assets of -57.88% is in line compared to the rest of the industry. KZR outperforms 43.37% of its industry peers.
KZR has a Return On Equity of -71.62%. This is comparable to the rest of the industry: KZR outperforms 53.94% of its industry peers.
Industry RankSector Rank
ROA -57.88%
ROE -71.62%
ROIC N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
KZR Yearly ROA, ROE, ROICKZR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZR Yearly Profit, Operating, Gross MarginsKZR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
KZR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KZR has less shares outstanding
KZR has a worse debt/assets ratio than last year.
KZR Yearly Shares OutstandingKZR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KZR Yearly Total Debt VS Total AssetsKZR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

KZR has an Altman-Z score of -4.55. This is a bad value and indicates that KZR is not financially healthy and even has some risk of bankruptcy.
KZR has a Altman-Z score of -4.55. This is comparable to the rest of the industry: KZR outperforms 42.11% of its industry peers.
KZR has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
KZR has a worse Debt to Equity ratio (0.04) than 61.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -4.55
ROIC/WACCN/A
WACC9.37%
KZR Yearly LT Debt VS Equity VS FCFKZR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

KZR has a Current Ratio of 6.76. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.76, KZR is in the better half of the industry, outperforming 65.23% of the companies in the same industry.
KZR has a Quick Ratio of 6.76. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.76, KZR is doing good in the industry, outperforming 65.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.76
Quick Ratio 6.76
KZR Yearly Current Assets VS Current LiabilitesKZR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

KZR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.59%.
Looking at the last year, KZR shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-156.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KZR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.18% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.53%
EPS Next 2Y18.25%
EPS Next 3Y12.9%
EPS Next 5Y11.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KZR Yearly Revenue VS EstimatesKZR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 2031 2032 50M 100M 150M 200M 250M
KZR Yearly EPS VS EstimatesKZR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KZR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZR Price Earnings VS Forward Price EarningsKZR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZR Per share dataKZR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as KZR's earnings are expected to grow with 12.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.25%
EPS Next 3Y12.9%

More info and screens

0

5. Dividend

5.1 Amount

KZR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEZAR LIFE SCIENCES INC

NASDAQ:KZR (6/23/2025, 8:00:02 PM)

After market: 4.21 -0.05 (-1.17%)

4.26

-0.26 (-5.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners56.65%
Inst Owner Change-34.48%
Ins Owners2.17%
Ins Owner Change0%
Market Cap31.14M
Analysts78
Price Target12.75 (199.3%)
Short Float %0.78%
Short Ratio1.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.76%
Min EPS beat(2)4.91%
Max EPS beat(2)12.62%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.91%
Max EPS beat(4)16.56%
EPS beat(8)5
Avg EPS beat(8)3.47%
EPS beat(12)9
Avg EPS beat(12)5.46%
EPS beat(16)11
Avg EPS beat(16)4.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)0%
EPS NY rev (3m)9.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.27
EV/EBITDA N/A
EPS(TTM)-10.52
EYN/A
EPS(NY)-6.77
Fwd EYN/A
FCF(TTM)-10.16
FCFYN/A
OCF(TTM)-10.15
OCFYN/A
SpS0
BVpS15.99
TBVpS15.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.88%
ROE -71.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.76
Quick Ratio 6.76
Altman-Z -4.55
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)109.16%
Cap/Depr(5y)72.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.33%
EPS Next Y24.53%
EPS Next 2Y18.25%
EPS Next 3Y12.9%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.1%
OCF growth 3YN/A
OCF growth 5YN/A